Journal
NATURE MEDICINE
Volume 7, Issue 7, Pages 847-852Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/89977
Keywords
-
Funding
- NHLBI NIH HHS [HL 54591] Funding Source: Medline
Ask authors/readers for more resources
Increased secretion and levels of ApoB-containing lipoproteins (BLp) commonly occur in familiar hyperlipidemia, obesity and diabetes. The plasma phospholipid-transfer protein (PLTP) is known to mediate transfer of phospholipids between BLp and HDL during their intravascular metabolism. To address a possible role of PLTP in dyslipidemia and atherogenesis, we bred mice deficient in the gene encoding PLTP (PLTP-deficient mice) using different hyperlipidemic mouse strains. In ApoB-transgenic and ApoE-deficient backgrounds, PLTP deficiency resulted in reduced production and levels of BLp and markedly decreased atherosclerosis. BLp secretion was diminished in hepatocytes from ApoB-transgenic PLTP-deficient mice, a defect that was corrected when PLTP was reintroduced in adenovirus. The studies reveal a major, unexpected role of PLTP in regulating the secretion of BLp and identify PLTP as a therapeutic target.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available